A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies-Reference-Cited by-同舟云学术

A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

Published:2015-01-07 Issue:8 Volume:23 Page:2231-2244
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Chan Alexandre,Cameron Michael C.,Garden Benjamin,Boers-Doets Christine B.,Schindler Katja,Epstein Joel B.,Choi Jennifer,Beamer Laura,Roeland Eric,Russi Elvio G.,Bensadoun René-Jean,Teo Yi Ling,Chan Raymond J.,Shih Vivianne,Bryce Jane,Raber-Durlacher Judith,Gerber Peter Arne,Freytes César O.,Rapoport Bernardo,LeBoeuf Nicole,Sibaud Vincent,Lacouture Mario E.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-014-2564-x.pdf

Reference30 articles.

1. Agha R, Kinahan K, Bennett CL, Lacouture ME (2007) Dermatologic challenges in cancer patients and survivors. Oncology (Williston Park, NY) 21(12):1462–1472, discussion 1473, 1476, 1481 passim

2. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME (2010) Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116(16):3916–3923. doi: 10.1002/cncr.25090

3. Chen A, Acharya A, Setser A (2013) Grading dermatologic adverse events in clinical trials using CTCAE v4.0. In: dermatologic principles and practice in oncology. Wiley, New Jersey, pp 47–59. doi: 10.1002/9781118590638.ch5

4. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol 7(11):903–909. doi: 10.1016/s1470-2045(06)70910-x

5. Basch E (2012) Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health: J Int Soc Pharmacoeconomics Outcomes Res 15(3):401–403. doi: 10.1016/j.jval.2012.03.1385

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors;Supportive Care in Cancer;2022-09-03

2. Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management;International Journal of Women's Dermatology;2021-12

3. Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT;Chronic Illness;2021-11-17

4. Dermatologic adverse events associated with targeted therapies for melanoma;Expert Opinion on Drug Safety;2021-11-02

5. Radiation-Induced Skin Dermatitis: Treatment With CamWell® Herb to Soothe® Cream in Patients With Head and Neck Cancer Receiving Radiation Therapy;Clinical Journal of Oncology Nursing;2021-08-01